Dr. Robert Sidonio JR., MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
GA license 73001
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 12 companies reported 90 payments worth $136,175 in total to this clinician.
| Octapharma USA, Inc. | $31,786 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $31,736 |
| Hema Biologics, LLC | $20,132 |
| Novo Nordisk Inc | $14,382 |
| Pfizer Inc. | $12,255 |
| Genentech USA, Inc. | $11,880 |
| Swedish Orphan Biovitrum Ab | $6,580 |
| Novo Nordisk Health Care AG | $2,620 |
| Consulting Fee | $52,096 |
|---|---|
| Honoraria | $35,036 |
| Compensation for services other than consulting (speaking, faculty) | $26,583 |
| Travel and Lodging | $21,244 |
| Food and Beverage | $1,216 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Jun 22, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $7,041 |
| Genentech USA, Inc. Jul 10, 2025 | Consulting Fee Hemlibra · Hematology | $6,560 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 20, 2025 | Consulting Fee ADYNOVATE · HEMATOLOGY | $6,424 |
| Hema Biologics, LLC Nov 27, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $6,030 |
| Hema Biologics, LLC Feb 12, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,695 |
| Octapharma USA, Inc. Sep 14, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to PADUA, Italy | $5,078 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) FEIBA · HEMATOLOGY · in-kind | $5,046 |
| Hema Biologics, LLC May 7, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,000 |
| Swedish Orphan Biovitrum Ab Jan 31, 2025 | Consulting Fee Alprolix · Hematology | $4,700 |
| Pfizer Inc. Apr 15, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $4,500 |
All 72 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Octapharma USA, Inc. Dec 5, 2025 | Honoraria NUWIQ · COAGULATION | $2,500 |
| Octapharma USA, Inc. Dec 5, 2025 | Travel and Lodging NUWIQ · COAGULATION · travel to ORLANDO, FL | $490 |
| Octapharma USA, Inc. Dec 5, 2025 | Travel and Lodging NUWIQ · COAGULATION · travel to ORLANDO, FL | $299 |
| Hema Biologics, LLC Nov 27, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $6,030 |
| Genentech, Inc. Nov 25, 2025 | Consulting Fee Hemlibra · Hematology | $1,520 |
| Octapharma USA, Inc. Nov 20, 2025 | Honoraria FIBRYGA & BALFAXAR · INTENSIVE CAREEMERGENCY | $3,000 |
| Octapharma USA, Inc. Nov 20, 2025 | Travel and Lodging FIBRYGA & BALFAXAR · INTENSIVE CAREEMERGENCY · travel to PARAMUS, NJ | $532 |
| Octapharma USA, Inc. Nov 20, 2025 | Travel and Lodging FIBRYGA & BALFAXAR · INTENSIVE CAREEMERGENCY · travel to PARAMUS, NJ | $268 |
| Octapharma USA, Inc. Nov 20, 2025 | Travel and Lodging FIBRYGA & BALFAXAR · INTENSIVE CAREEMERGENCY · travel to PARAMUS, NJ | $140 |
| Octapharma USA, Inc. Nov 20, 2025 | Travel and Lodging FIBRYGA & BALFAXAR · INTENSIVE CAREEMERGENCY · travel to PARAMUS, NJ | $112 |
| Octapharma USA, Inc. Nov 20, 2025 | Travel and Lodging FIBRYGA & BALFAXAR · INTENSIVE CAREEMERGENCY · travel to PARAMUS, NJ | $112 |
| Octapharma USA, Inc. Nov 20, 2025 | Travel and Lodging FIBRYGA & BALFAXAR · INTENSIVE CAREEMERGENCY · travel to PARAMUS, NJ | $61.43 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 19, 2025 | Consulting Fee FEIBA · HEMATOLOGY | $3,938 |
| Csl Behring Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Humate-P · Hematology · in-kind | $444 |
| Octapharma USA, Inc. Sep 14, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to PADUA, Italy | $5,078 |
| Octapharma USA, Inc. Sep 14, 2025 | Honoraria WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION | $2,500 |
| Octapharma USA, Inc. Sep 14, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to PADUA, Italy | $223 |
| Octapharma USA, Inc. Sep 14, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to PADUA, Italy | $223 |
| Pfizer Inc. Sep 8, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $3,000 |
| Diagnostica Stago Sas Aug 26, 2025 | Honoraria | $466 |
| Novo Nordisk Inc Aug 22, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $19.58 |
| Hema Biologics, LLC Aug 9, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $2,345 |
| Novo Nordisk Inc Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,638 |
| Novo Nordisk Health Care AG Jul 25, 2025 | Consulting Fee | $1,965 |
| Novo Nordisk Health Care AG Jul 25, 2025 | Consulting Fee | $655 |
| Csl Behring Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) Humate-P · Hematology · in-kind | $259 |
| Novo Nordisk Inc Jul 22, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,638 |
| Novo Nordisk Inc Jul 21, 2025 | Consulting FeeCompany’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $2,620 |
| Genentech USA, Inc. Jul 10, 2025 | Consulting Fee Hemlibra · Hematology | $6,560 |
| Genentech USA, Inc. Jul 10, 2025 | Travel and Lodging Hemlibra · Hematology · travel to South San Francisco, CA | $1,722 |
| Genentech USA, Inc. Jul 10, 2025 | Travel and Lodging Hemlibra · Hematology · travel to South San Francisco, CA | $1,297 |
| Genentech USA, Inc. Jul 10, 2025 | Travel and Lodging Hemlibra · Hematology · travel to South San Francisco, CA | $346 |
| Octapharma USA, Inc. Jun 25, 2025 | Honoraria WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION | $2,500 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $686 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Novo Nordisk Inc Jun 22, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $7,041 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 20, 2025 | Consulting Fee ADYNOVATE · HEMATOLOGY | $6,424 |
| Genentech USA, Inc. Jun 20, 2025 | Consulting Fee Hemlibra · Hematology | $1,640 |
| Csl Behring Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) Humate-P · Hematology · in-kind | $832 |
| Pfizer Inc. Jun 11, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $3,000 |
| Takeda Pharmaceuticals U.S.A., Inc. May 29, 2025 | Consulting Fee | $2,811 |
| Novo Nordisk Inc May 27, 2025 | Consulting FeeCompany’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,310 |
| Octapharma USA, Inc. May 10, 2025 | Honoraria WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION | $2,500 |
| Octapharma USA, Inc. May 10, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to LOUISVILLE, KY | $842 |
| Octapharma USA, Inc. May 10, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to LOUISVILLE, KY | $253 |
| Octapharma USA, Inc. May 10, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to LOUISVILLE, KY | $253 |
| Octapharma USA, Inc. May 10, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to LOUISVILLE, KY | $253 |
| Hema Biologics, LLC May 7, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,000 |
| Hema Biologics, LLC Apr 24, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to MILAN, Italy | $912 |
| Pfizer Inc. Apr 15, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $4,500 |
| Genentech, Inc. Apr 3, 2025 | Consulting Fee Hemlibra · Hematology | $760 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) FEIBA · HEMATOLOGY · in-kind | $5,046 |
| Pfizer Inc. Mar 14, 2025 | Travel and Lodging travel to Coronado, CA · in-kind | $884 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) FEIBA · HEMATOLOGY | $3,413 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 4, 2025 | Consulting Fee FEIBA · HEMATOLOGY | $3,413 |
| Hema Biologics, LLC Feb 12, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,695 |
| Swedish Orphan Biovitrum Ab Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) Alprolix · Hematology | $1,880 |
| Octapharma USA, Inc. Feb 7, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to MILAN, Italy | $3,426 |
| Octapharma USA, Inc. Feb 7, 2025 | Honoraria WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION | $2,500 |
| Octapharma USA, Inc. Feb 7, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to MILAN, Italy | $279 |
| Octapharma USA, Inc. Feb 7, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to MILAN, Italy | $279 |
| Octapharma USA, Inc. Feb 7, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to MILAN, Italy | $279 |
| Swedish Orphan Biovitrum Ab Jan 31, 2025 | Consulting Fee Alprolix · Hematology | $4,700 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 24, 2025 | Consulting Fee FEIBA · HEMATOLOGY | $3,281 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 24, 2025 | Compensation for services other than consulting (speaking, faculty) CEPROTIN · IMMUNOLOGY | $3,263 |
| Csl Behring Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) Humate-P · Hematology · in-kind | $379 |
| Pfizer Inc. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $182,275 in research payments for these studies, mostly to the institutions running them.
- A retrospective analysis of the Safety, Effectiveness during surgery with recombinant Von Willebrand Factor (rVWF) in children with Von Willebrand Disease (VWD) in the ATHNdataset
Takeda Pharmaceuticals U.S.A., Inc. - A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT02615691 - Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Csl Behring · Recruiting · NCT07080905
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.